NanoCure: A Medical Grade Nanoneedle Bandage for Topical COL7A1 Gene Therapy
Lay summary
Supported by Cure EB (NanoCol), our team has developed NanoCure, a bandage designed to improve wound healing in recessive dystrophic epidermolysis bullosa (RDEB). NanoCure’s surface contains millions of painless, non-toxic tiny needles called nanoneedles that effectively deliver genes into cells. In a mouse model, we showed that these needles can introduce a copy of the missing collage VII gene, helping cells produce the collagen needed to heal wounds in RDEB. This project aims to refine NanoCure in preparation for patient trials.
Scientific Summary
With support from Cure EB (NanoCol), we demonstrated that NanoCure, a nanoneedle bandage delivering COL7A1 plasmid, restores type VII Collagen (C7) at the dermal-epidermal junction in a mouse model of recessive dystrophic epidermolysis bullosa (RDEB). This project develops a medical-grade NanoCure bandage and prepares for first-in-human trials. We will design and manufacture 80 NanoCure bandages with final product specifications. Sterility, safety, and efficacy will be validated according to Good Laboratory Practices. Finally, we will compile and submit the necessary documentation to the UK Medicines and Healthcare products Regulatory Agency for approval of a first-in-human clinical investigation.
